32.25 USD
-1.6 (-4.73%)
32.17 USD
-0.08 (-0.25%)
GMAB gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. GMAB scores excellent points on both the profitability and health parts. This is a solid base for a good stock. GMAB is growing strongly while it is still valued neutral. This is a good combination! These ratings could make GMAB a good candidate for growth and quality investing.
1. Profitability
1.1 Basic Checks
- In the past year GMAB was profitable.
- GMAB had a positive operating cash flow in the past year.
- Each year in the past 5 years GMAB has been profitable.
- GMAB had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- GMAB's Return On Assets of 21.10% is amongst the best of the industry. GMAB outperforms 97.33% of its industry peers.
- GMAB has a Return On Equity of 25.76%. This is amongst the best in the industry. GMAB outperforms 97.14% of its industry peers.
- GMAB has a Return On Invested Capital of 17.11%. This is amongst the best in the industry. GMAB outperforms 96.76% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for GMAB is below the industry average of 18.07%.
- The last Return On Invested Capital (17.11%) for GMAB is above the 3 year average (15.20%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 21.1% | ||
| ROE | 25.76% | ||
| ROIC | 17.11% |
ROA(3y)15.92%
ROA(5y)16.24%
ROE(3y)18.48%
ROE(5y)18.5%
ROIC(3y)15.2%
ROIC(5y)16.1%
1.3 Margins
- GMAB's Profit Margin of 41.35% is amongst the best of the industry. GMAB outperforms 97.33% of its industry peers.
- GMAB's Profit Margin has declined in the last couple of years.
- The Operating Margin of GMAB (36.85%) is better than 97.90% of its industry peers.
- GMAB's Operating Margin has declined in the last couple of years.
- GMAB has a Gross Margin of 94.27%. This is amongst the best in the industry. GMAB outperforms 94.86% of its industry peers.
- In the last couple of years the Gross Margin of GMAB has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 36.85% | ||
| PM (TTM) | 41.35% | ||
| GM | 94.27% |
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so GMAB is creating value.
- Compared to 1 year ago, GMAB has less shares outstanding
- The number of shares outstanding for GMAB has been reduced compared to 5 years ago.
- The debt/assets ratio for GMAB is higher compared to a year ago.
2.2 Solvency
- GMAB has an Altman-Z score of 11.96. This indicates that GMAB is financially healthy and has little risk of bankruptcy at the moment.
- GMAB has a Altman-Z score of 11.96. This is amongst the best in the industry. GMAB outperforms 84.00% of its industry peers.
- GMAB has a debt to FCF ratio of 0.12. This is a very positive value and a sign of high solvency as it would only need 0.12 years to pay back of all of its debts.
- With an excellent Debt to FCF ratio value of 0.12, GMAB belongs to the best of the industry, outperforming 95.81% of the companies in the same industry.
- GMAB has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
- With a Debt to Equity ratio value of 0.02, GMAB perfoms like the industry average, outperforming 43.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.12 | ||
| Altman-Z | 11.96 |
ROIC/WACC2.34
WACC7.32%
2.3 Liquidity
- GMAB has a Current Ratio of 6.03. This indicates that GMAB is financially healthy and has no problem in meeting its short term obligations.
- GMAB's Current ratio of 6.03 is fine compared to the rest of the industry. GMAB outperforms 62.86% of its industry peers.
- GMAB has a Quick Ratio of 6.01. This indicates that GMAB is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 6.01, GMAB is in the better half of the industry, outperforming 63.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.03 | ||
| Quick Ratio | 6.01 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 125.90% over the past year.
- The Earnings Per Share has been growing by 28.38% on average over the past years. This is a very strong growth
- The Revenue has grown by 24.66% in the past year. This is a very strong growth!
- GMAB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 31.16% yearly.
EPS 1Y (TTM)125.9%
EPS 3Y34.24%
EPS 5Y28.38%
EPS Q2Q%121.44%
Revenue 1Y (TTM)24.66%
Revenue growth 3Y32.63%
Revenue growth 5Y31.16%
Sales Q2Q%-81.55%
3.2 Future
- GMAB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.30% yearly.
- GMAB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.38% yearly.
EPS Next Y2.82%
EPS Next 2Y-0.05%
EPS Next 3Y7.32%
EPS Next 5Y9.3%
Revenue Next Year22.77%
Revenue Next 2Y19.6%
Revenue Next 3Y17.39%
Revenue Next 5Y13.38%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 13.67, the valuation of GMAB can be described as correct.
- GMAB's Price/Earnings ratio is rather cheap when compared to the industry. GMAB is cheaper than 96.76% of the companies in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 27.38, GMAB is valued rather cheaply.
- GMAB is valuated rather expensively with a Price/Forward Earnings ratio of 18.29.
- 94.48% of the companies in the same industry are more expensive than GMAB, based on the Price/Forward Earnings ratio.
- GMAB is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 24.29, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.67 | ||
| Fwd PE | 18.29 |
4.2 Price Multiples
- 96.76% of the companies in the same industry are more expensive than GMAB, based on the Enterprise Value to EBITDA ratio.
- Based on the Price/Free Cash Flow ratio, GMAB is valued cheaply inside the industry as 96.19% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.51 | ||
| EV/EBITDA | 10.78 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates GMAB does not grow enough to justify the current Price/Earnings ratio.
- GMAB has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)4.85
PEG (5Y)0.48
EPS Next 2Y-0.05%
EPS Next 3Y7.32%
5. Dividend
5.1 Amount
- GMAB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
32.25
-1.6 (-4.73%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)02-05 2026-02-05/amc
Inst Owners44.16%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap19.87B
Revenue(TTM)3.58B
Net Income(TTM)1.48B
Analysts71.85
Price Target28.4 (-11.94%)
Short Float %1.95%
Short Ratio6.34
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.75%
Min EPS beat(2)25.14%
Max EPS beat(2)36.36%
EPS beat(4)4
Avg EPS beat(4)61.45%
Min EPS beat(4)25.14%
Max EPS beat(4)134.67%
EPS beat(8)6
Avg EPS beat(8)30.99%
EPS beat(12)8
Avg EPS beat(12)16.81%
EPS beat(16)12
Avg EPS beat(16)30.22%
Revenue beat(2)1
Avg Revenue beat(2)-0.2%
Min Revenue beat(2)-1.49%
Max Revenue beat(2)1.09%
Revenue beat(4)2
Avg Revenue beat(4)-1.55%
Min Revenue beat(4)-7.66%
Max Revenue beat(4)1.87%
Revenue beat(8)6
Avg Revenue beat(8)300.02%
Revenue beat(12)10
Avg Revenue beat(12)350.69%
Revenue beat(16)14
Avg Revenue beat(16)264.87%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0.82%
EPS NQ rev (3m)0.61%
EPS NY rev (1m)0.04%
EPS NY rev (3m)7.97%
Revenue NQ rev (1m)0.29%
Revenue NQ rev (3m)-0.19%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.48%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.67 | ||
| Fwd PE | 18.29 | ||
| P/S | 5.54 | ||
| P/FCF | 16.51 | ||
| P/OCF | 15.58 | ||
| P/B | 3.45 | ||
| P/tB | 5.45 | ||
| EV/EBITDA | 10.78 |
EPS(TTM)2.36
EY7.32%
EPS(NY)1.76
Fwd EY5.47%
FCF(TTM)1.95
FCFY6.06%
OCF(TTM)2.07
OCFY6.42%
SpS5.82
BVpS9.34
TBVpS5.92
PEG (NY)4.85
PEG (5Y)0.48
Graham Number22.27
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 21.1% | ||
| ROE | 25.76% | ||
| ROCE | 21.02% | ||
| ROIC | 17.11% | ||
| ROICexc | 37.46% | ||
| ROICexgc | 140.29% | ||
| OM | 36.85% | ||
| PM (TTM) | 41.35% | ||
| GM | 94.27% | ||
| FCFM | 33.59% |
ROA(3y)15.92%
ROA(5y)16.24%
ROE(3y)18.48%
ROE(5y)18.5%
ROIC(3y)15.2%
ROIC(5y)16.1%
ROICexc(3y)68.77%
ROICexc(5y)79.83%
ROICexgc(3y)104.16%
ROICexgc(5y)104.49%
ROCE(3y)18.68%
ROCE(5y)19.78%
ROICexgc growth 3Y22.66%
ROICexgc growth 5Y11.4%
ROICexc growth 3Y-22.7%
ROICexc growth 5Y-14.09%
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
F-Score7
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.12 | ||
| Debt/EBITDA | 0.09 | ||
| Cap/Depr | 106.94% | ||
| Cap/Sales | 1.98% | ||
| Interest Coverage | 243.04 | ||
| Cash Conversion | 91.92% | ||
| Profit Quality | 81.24% | ||
| Current Ratio | 6.03 | ||
| Quick Ratio | 6.01 | ||
| Altman-Z | 11.96 |
F-Score7
WACC7.32%
ROIC/WACC2.34
Cap/Depr(3y)96.21%
Cap/Depr(5y)101.76%
Cap/Sales(3y)1.96%
Cap/Sales(5y)2.38%
Profit Quality(3y)107.36%
Profit Quality(5y)103.53%
High Growth Momentum
Growth
EPS 1Y (TTM)125.9%
EPS 3Y34.24%
EPS 5Y28.38%
EPS Q2Q%121.44%
EPS Next Y2.82%
EPS Next 2Y-0.05%
EPS Next 3Y7.32%
EPS Next 5Y9.3%
Revenue 1Y (TTM)24.66%
Revenue growth 3Y32.63%
Revenue growth 5Y31.16%
Sales Q2Q%-81.55%
Revenue Next Year22.77%
Revenue Next 2Y19.6%
Revenue Next 3Y17.39%
Revenue Next 5Y13.38%
EBIT growth 1Y41.76%
EBIT growth 3Y29.8%
EBIT growth 5Y21.02%
EBIT Next Year56.34%
EBIT Next 3Y28.03%
EBIT Next 5Y19.44%
FCF growth 1Y46.62%
FCF growth 3Y51.06%
FCF growth 5Y42.84%
OCF growth 1Y44.68%
OCF growth 3Y47.08%
OCF growth 5Y41.48%
GENMAB A/S -SP ADR / GMAB FAQ
What is the ChartMill fundamental rating of GENMAB A/S -SP ADR (GMAB) stock?
ChartMill assigns a fundamental rating of 7 / 10 to GMAB.
What is the valuation status for GMAB stock?
ChartMill assigns a valuation rating of 6 / 10 to GENMAB A/S -SP ADR (GMAB). This can be considered as Fairly Valued.
Can you provide the profitability details for GENMAB A/S -SP ADR?
GENMAB A/S -SP ADR (GMAB) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for GMAB stock?
The Price/Earnings (PE) ratio for GENMAB A/S -SP ADR (GMAB) is 13.67 and the Price/Book (PB) ratio is 3.45.
Can you provide the financial health for GMAB stock?
The financial health rating of GENMAB A/S -SP ADR (GMAB) is 8 / 10.